Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Clopidogrel is a P2Y12 inhibitor, widely prescribed as antiplatelet therapy for acute coronary syndromes and following percutaneous coronary intervention.
• While generally safe, drug-induced liver injury is a potential, albeit rare, adverse effect associated with clopidogrel use.

Observation:

• A 74-year-old male patient developed symptomatic liver disease approximately five weeks after initiating clopidogrel therapy.
• The patient's presentation included signs and symptoms indicative of liver dysfunction.

Findings:

• This case represents a rare instance of clopidogrel-induced hepatotoxicity.
• Review of existing literature indicates that clopidogrel-induced liver injury, though infrequent, can manifest as symptomatic liver disease.

Implications:

• Clinicians should maintain awareness of potential hepatotoxicity as a rare adverse event in patients treated with clopidogrel.
• Prompt recognition and evaluation are crucial for managing clopidogrel-induced liver injury and considering alternative antiplatelet strategies if necessary.